Acquisition / mergerFiled on BSE ·
Bajaj Healthcare Limited announces unaudited Q2 and H1 FY2026-27 financial results
Bajaj Healthcare · Pharmaceuticals & Biotechnology
What the filing says
- Board approved and audited by Walker Chandiok & Co on 17 October 2026; results under Ind AS
- H1 FY2026 revenue ₹341.53 crore, net profit after tax ₹27.79 crore; discontinued operations loss ₹0.48 crore
- Completed sale of Tarepur and Dahej units; acquired Genrx Pharmaceuticals pending NCLT approval as subsidiary
Original filing
Board Meeting Outcome for Outcome Of The Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Bajaj Healthcare
- Financial resultsBajaj Healthcare Ltd announces unaudited Q2 & H1 FY27 financial results and key updates
- Acquisition / mergerBajaj Healthcare reports Q2 & H1 FY27 results with revenue and profit growth
- Acquisition / mergerBajaj Healthcare Limited received NCLT approval for acquisition of Genrx Pharmaceuticals
Other acquisition / merger filings this fortnight
- Acquisition / mergerZen TechnologiesZen Technologies to acquire 51.98% stake in Cogknit Semantics for ₹135.15 crore
- Acquisition / mergerAmber Enterprises India LtdAmber Enterprises' subsidiary IL JIN acquires remaining 40% stake in Power-One
- Acquisition / mergerAmber Enterprises India LtdAmber Enterprises subsidiary IL JIN acquires 40% stake in Power-One via share swap
- Acquisition / mergerKPI Green Energy LtdKPI Green Energy’s subsidiary Sun Drops Energia acquires 88.37% stake in DMGEL
- Acquisition / mergerZen TechnologiesZen Technologies to acquire 51.98% stake in Cogknit Semantics for ₹135.15 crore
- Acquisition / mergerJSW SteelJSW Steel Limited announces NCLT sanction of Scheme of Amalgamation with Piombino Steel Limited
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.